Inclusion Criteria

DISEASE CHARACTERISTICS:

- Biopsy confirmed uterine (malignant mixed müllerian tumor) or ovarian carcinosarcoma
meeting ≥ 1 of the following criteria:

- Newly diagnosed disease

- Stage I-IV* disease

- Persistent or recurrent disease

- Chemotherapy-naive disease NOTE: *Unstaged patients (patients who have not had
hysterectomy surgery) are eligible and should be included as "unstaged" if the
only histologic (pathology) documentation of the disease is a biopsy or
curettage of the uterus or ovary; if these patients have documented metastatic
disease, it should be assigned the appropriate stage (III/IV)

- Measurable or nonmeasurable disease

- Measurable disease is defined as ≥ 1 lesion that can be accurately measured in ≥
1 dimension as ≥ 20 mm by conventional techniques (e.g., palpation, plain s-ray,
CT scan, MRI) or ≥ 10 mm by spiral CT scan

- Patients with measurable disease must have ≥ 1 "target lesion" to be used to
assess disease progression as defined by RECIST criteria

- Tumors within a previously irradiated field will be designated as "non-target"
lesions unless progression is documented or a biopsy is obtained to confirm
persistence ≥ 90 days after completion of radiotherapy

PATIENT CHARACTERISTICS:

- GO performance status 0-2

- Platelet count ≥ 100,000/mm^3

- ANC ≥ 1,500/mm^3

- Creatinine ≤ 1.5 times upper limit of normal (ULN)

- Bilirubin ≤ 1.5 times ULN

- SGOT ≤ 2.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

- Serum albumin ≥ 3 g/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Neuropathy (sensory and motor) ≤ CTCAE v3.0 grade 1

- No active infection requiring antibiotics

- No concurrent or history of other invasive malignancies, except for nonmelanoma skin
cancer, within the past 5 years

- No known hypersensitivity to E. coli-derived drug preparations (pegfilgrastim and
filgrastim [G-CSF]), mesna, or other thiol compounds

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from the effects of recent surgery, radiotherapy, or other therapy

- No prior cytotoxic chemotherapy for management of uterine or ovarian carcinosarcoma

- No prior cancer treatment that contraindicates this protocol therapy

- At least 4 weeks since prior adjuvant external beam radiotherapy

- At least 1 week since prior hormonal therapy directed at the malignant tumor

- Continuation of hormone replacement therapy allowed

- No planned radiotherapy after or during study treatment prior to progression of
cancer